The UK is home to a world class healthcare & life sciences ecosystem.







The UK is home to a world class healthcare & life sciences ecosystem.

- We recognise the challenges and opportunities of an ageing population and are harnessing our ecosystem towards solutions.
- DBT is supporting trade and investment opportunities across the Healthy Ageing pathway.

Early intervention products and therapeutics for Healthy Ageing Linda Magee 23 November 2023





The <u>UK's Life Science</u> <u>Strategy</u> identifies Healthy Ageing as one of four advanced research areas



The UK is also keen on sharing its expertise overseas and learn from other countries...


UK Government is still committed to ensuring that people can enjoy healthy, independent years of lives




The <u>NHS Long Term Plan</u> is developed specifically to support people as they get older



National Health Service



System Overview (England)



Supporting Care at home: Virtual Wards (NHSE)

Create **Virtual Wards**, equivalent to district general hospital (around 500 beds each), in each ICS by 2025.

- Care at home rather than hospital.
- 'Hospital at Home': remote monitoring using apps, technology platforms, wearables and medical devices and
- face-to-face care from community based multidisciplinary teams


Initial priorities:

- Acute respiratory infections
- Frail then adding Other highvolume pathways such as COPD and heart failure.

Install electronic patient records at every NHS trust (must cover 90 per cent of NHS trusts by December 2023)

 Plus 80 per cent of social care settings to have digital care records by March 2024

Health Innovation Ecosystem



Market Access: Selling into the NHS

Medicines:

- 1. MHRA is regulator for market access authorisation
- 2. NIHR support clinical studies for regulatory authorities
- NICE evaluates benefit to patients and affordability for NHS allowing for reimbursement
- 4. The Commercial Medicines Unit, within NHSE, manages national procurement frameworks for licenced medicines in England.
- 5. Medicines are delivered in hospital, community and home setting and dispensed in hospitals and community pharmacies.

MedTech:

- 1. MHRA is regulator for market access authorisation (UKCA mark)
- 2. NIHR support clinical studies for regulatory authorities
- 3. NICE evaluates benefit to patients and affordability for NHS and assesses all guidance to understand which technologies meet the criteria for the MedTech Mandate on an annual basis
- 4. Various routes exist to sell to the NHS
 - Direct to Trusts or Primary Care
 - NHS Supply Chain
 - National Frameworks
 - Government or NHS Contracts (includes Local Authorities), see 'NHS family' e- tendering portal:

All products and services can potentially benefit from the Innovation Pathway and Accelerated Access Programme via the **NHS Innovation Service** at: <u>https://innovation.nhs.uk/</u>